ORTEXORTEX News
Live short interest, options flow, and signals — free on ORTEX.Sign up free →
Market Commentary

Bears Pile In: Braveheart Bio Tops the Short List

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 1 min read

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

Short sellers are circling hard this week. BRVE (Braveheart Bio) sits at an extraordinary 352% short interest as a percentage of free float. That jumped from 191% just seven days ago — a 161 percentage-point surge. No shares are readily available to borrow at any meaningful premium.

WOLF (Wolfspeed) remains one of the most-shorted large names. SI % FF hit 80.7%, though bears trimmed slightly by 2.9 points week-on-week. Zero availability signals extreme crowding.

CHWY (Chewy) carries a hefty 74% SI % FF. Unusually, availability stands at 405% — suggesting short sellers could easily add more. That sets up a watching brief for any squeeze catalyst.

MMED (MiniMed Group) saw SI % FF climb to 42%, up 8.5 points in a week. Cost to borrow has risen to 19.4%. Bears are paying up to stay short.

EVCM (EverCommerce) tops the short-score rankings. Cost to borrow hit 66.6% annually. That is punishing for any position held long-term.

On the other side, M (Macy's) saw shorts retreat 3.4 points to 13.7% — a notable cover in a tough retail environment. WOLF also saw modest short covering despite its high absolute level.

Broader market sentiment remains fragile. The Nasdaq fell over 1% Wednesday as Treasury yields climbed. Fear & Greed remains firmly in "Fear" territory — fertile ground for short sellers to stay active.

Stocks in this article

How this article was generated

Generated
24 Sept 2026, 08:04
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilization

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.